Back

Contemporary characteristics and treatment patterns of patients with HFmrEF and HFpEF in Germany. A cross-sectional survey.

9 May 2026 (09:30 - 10:15)
Organised by: Logo
Congress Presentation Part of: From classic drugs to new interventions in heart failure Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alexander Michel

Bayer AG, Basel (Switzerland)

5 More presentations in this session

Presentation thumbnail
Efficacy and safety of guideline-directed medical therapies according to background use of digoxin: Insights from RALES, PARADIGM-HF, and DAPA-HF
Doctor R. Helseth (Boston, US)
Abstract Slides Video
Presentation thumbnail
Back to the future - digitalis therapy reloaded? The suitability for digitoxin treatment in a real-world, outpatient heart failure patient cohort
Miss K. Czurko (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Six-month results from the ATHENS-HF FIH trial of the Adona Medical adjustable, biatrial pressure sensing interatrial shunt
Doctor K. Rommel (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Role of ferric carboxymaltose supplementation on comprehensive geriatric assessment in elderly patients with chronic heart failure
Doctor M. Scarcelli (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
The positive effect of sacubitril/valsartan therapy on QRS width and QTC interval on electrocardiogram in heart failure patients with reduced ejection fraction
Doctor P. Kekovic (Prokuplje, RS)
Abstract Slides Video

Access the full session

Session thumbnail
From classic drugs to new interventions in heart failure

The Event

Event poster

Heart Failure 2026

9 May 2026 09:30 CET
You may be interested in
thumbnail
Congress Presentation
Prescribing trends of sodium-glucose cotransporter 2 Inhibitors in patients with heart failure with preserved, mildly reduced and reduced ejection fraction
thumbnail
Congress Presentation
Unveiling gaps in heart failure management in Germany: a retrospective analysis of national data and healthcare utilisation patterns
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources